ST6Gal I调控胃癌细胞SGC7901增殖迁移能力的初步研究

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (5125 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the effect of α2, 6 sialytransferase (ST6Gal I) on the abilities of proliferation and migration in SGC7901 cells. Methods: Gastric cancer cell lines SGC7901 were constructed to ST6Gal I high expression (PS7) and ST6Gal I lower expression (X61) with lipofectamine 2000 and empty vector (Vector) was used as a control group. The expression of ST6Gal I was examined with RT-PCR. Cell proliferation was evaluated with the CCK-8 kit, and migration was evaluated with Transwell chamber assay. Results: The 3 stable transfected cell lines were constructed successfully. The most effective clone cells were chosed as our experimental cells, and named as Vector, X61-4 and PS7. In contrasted with Vector, the expression of ST6GAL I in X61-4 was statistically significant lower (P<0.05), and PS7 was statistically significant higher (P<0.05). Cell growth curve showed that cell proliferation of X61-4
was obviously higher than that of PS7 cells (P<0.05). The transwell chamber assay results showed that the migration of PS7 was significantly higher than that of the X61-4 (P<0.01) and Vector (P<0.01), X61-4 was lower than that of the Vector (P<0.05). Conclusion: Cell experiment results show that lower ST6Gal I can effectively promote the proliferation ability of SGC7901 gastric cancer cells, but high ST6Gal I can enhance gastric cancer cell migration ability. Therefore, ST6Gal I is related to the tumor proliferation and metastasis, and it is also a potential tumor molecular therapeutic targets.

Key words： ST6Gal?I stomach neoplasms sialylation proliferation migration

Received: 29 October 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Menglu
	LIU Tingting
	PENG Xiaodan
	LIN Shaoqiang

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I4/235

[1] Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer[J]. World J Gastroenterol, 2011, 17(35): 3976-3985.
[2] Kim HJ, Eun JY, Jeon YW, et al. Efficacy and safety of oxaliplatin, 5-fluorouracil, and folinic acid combination chemotherapy as first-line treatment in metastatic or recurrent gastric cancer[J]. Cancer Res Treat, 2011, 43(3): 154-159.
[3] Reis CA, Osorio H, Silva L, et al. Alterations in glycosylation as biomarkers for cancer detection[J]. J Clin Pathol, 2010, 63(4): 322-329.
[4] Varki A, Kannagi R, Toole BP. Glycosylation changes in cancer[J]. Essentials of Glycobiology, 2009, Chapter 44:580-670.
[5] Drake PM, Cho WY, Li BS, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation[J]. Clin Chem, 2010, 56(2): 223-236.
[6] Harduin Lepers A, Vallejo Ruiz V, Krzewinski Recchi MA,et al. The human sialyltransferase family[J]. Biochimie,2001, 83(8): 727-737.
[7] Lee M, Park JJ, Ko YG, et al. Cleavage of ST6Gal I by radiation-induced BACE1 inhibits golgi-anchored ST6Gal I-mediated sialylation of integrin beta1 and migration in colon cancer cells[J]. Radiat Oncol, 2012, 7: 47.
[8] Dall’Olio F, Chiricolo M. Sialyltransferases in cancer[J]. Glycoconjugate J, 2001, 18(11-12): 41-850.
[9] Korekane H, Matsumoto A, Ota F, et al. Involvement of ST-6Gal I in the biosynthesis of a unique human colon cancer biomarker candidate, alpha2, 6-sialylated blood group type 2H(ST2H) antigen[J]. J Biochem, 2010, 148(3): 359-370.
[10] Lee M, Park JJ, Lee YS. Adhesion of ST6Gal I-mediated human colon cancer cells to fibronectin contributes to cell survival by integrin beta1-mediated paxillin and AKT activation[J]. Oncol Rep, 2010, 23(3): 757-761.
[11] Christie DR, Shaikh FM, Lucas JA, et al. ST6Gal I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function[J]. J Ovarian Res, 2008, 1(1): 3.
[12] Kitazume Kawaguchi S, Dohmae N, Takio K, et al. The relationship between ST6Gal I Golgi retention and its cleavage-secretion[J]. Glycobiology, 1999, 9(12): 1397-1406.
[13] Amano M, Galvan M, He J, et al. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering,
phosphatase modulation, and T cell death[J]. J Biol Chem, 2003, 278(9): 7469-7475.
[14] 苑天红, 李明远, 李婉宜, 等. 靶向ST6GALⅠ的siRNA与反义寡核苷酸联合应用对结肠癌细胞转移能力的影响[J].南方医科大学学报, 2007, 27(2): 136-140.
[15] Park JJ, Yi JY, Jin YB, et al. Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells[J]. Biochem Pharmacol, 2012, 83(7): 849-857.